HMGCR and COVID-19: Similarly, a Mendelian randomization study demonstrated that higher expressions of HMG-CoA reductase (HMGCR) and HMGCR-mediated LDL cholesterol were associated with a higher risk of COVID-19 hospitalization (odds ratio—OR 1.38, 95% CI 1.06–1.81 and OR 1.32, 95% CI 1.00–1.74, respectively) [51].